Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Advancing the Therapeutic Potential of Indoleamides for Tuberculosis.

Lun S, Tasneen R, Chaira T, Stec J, Onajole OK, Yang TJ, Cooper CB, Mdluli K, Converse PJ, Nuermberger EL, Raj VS, Kozikowski A, Bishai WR.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00343-19. doi: 10.1128/AAC.00343-19. Print 2019 Jul.

2.

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis.

Xu J, Li SY, Almeida DV, Tasneen R, Barnes-Boyle K, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e00021-19. doi: 10.1128/AAC.00021-19. Print 2019 May.

3.

A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.

Leung-Theung-Long S, Coupet CA, Gouanvic M, Schmitt D, Ray A, Hoffmann C, Schultz H, Tyagi S, Soni H, Converse PJ, Arias L, Kleinpeter P, Sansas B, Mdluli K, Vilaplana C, Cardona PJ, Nuermberger E, Marchand JB, Silvestre N, Inchausp├ę G.

PLoS One. 2018 May 2;13(5):e0196815. doi: 10.1371/journal.pone.0196815. eCollection 2018.

4.

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis.

Li SY, Tasneen R, Tyagi S, Soni H, Converse PJ, Mdluli K, Nuermberger EL.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00913-17. doi: 10.1128/AAC.00913-17. Print 2017 Sep.

5.

Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis.

Tantry SJ, Markad SD, Shinde V, Bhat J, Balakrishnan G, Gupta AK, Ambady A, Raichurkar A, Kedari C, Sharma S, Mudugal NV, Narayan A, Naveen Kumar CN, Nanduri R, Bharath S, Reddy J, Panduga V, Prabhakar KR, Kandaswamy K, Saralaya R, Kaur P, Dinesh N, Guptha S, Rich K, Murray D, Plant H, Preston M, Ashton H, Plant D, Walsh J, Alcock P, Naylor K, Collier M, Whiteaker J, McLaughlin RE, Mallya M, Panda M, Rudrapatna S, Ramachandran V, Shandil R, Sambandamurthy VK, Mdluli K, Cooper CB, Rubin H, Yano T, Iyer P, Narayanan S, Kavanagh S, Mukherjee K, Balasubramanian V, Hosagrahara VP, Solapure S, Ravishankar S, Hameed P S.

J Med Chem. 2017 Feb 23;60(4):1379-1399. doi: 10.1021/acs.jmedchem.6b01358. Epub 2017 Feb 3.

PMID:
28075132
6.

Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis.

Almeida D, Ioerger T, Tyagi S, Li SY, Mdluli K, Andries K, Grosset J, Sacchettini J, Nuermberger E.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4590-9. doi: 10.1128/AAC.00753-16. Print 2016 Aug.

7.

Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis.

Tasneen R, Betoudji F, Tyagi S, Li SY, Williams K, Converse PJ, Dartois V, Yang T, Mendel CM, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Oct 26;60(1):270-7. doi: 10.1128/AAC.01691-15. Print 2016 Jan.

8.

Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models.

Li SY, Irwin SM, Converse PJ, Mdluli KE, Lenaerts AJ, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Jul;59(7):4026-30. doi: 10.1128/AAC.00105-15. Epub 2015 Apr 27.

9.

The tuberculosis drug discovery and development pipeline and emerging drug targets.

Mdluli K, Kaneko T, Upton A.

Cold Spring Harb Perspect Med. 2015 Jan 29;5(6). pii: a021154. doi: 10.1101/cshperspect.a021154. Review.

10.

Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.

Tasneen R, Williams K, Amoabeng O, Minkowski A, Mdluli KE, Upton AM, Nuermberger EL.

Antimicrob Agents Chemother. 2015 Jan;59(1):129-35. doi: 10.1128/AAC.03822-14. Epub 2014 Oct 20.

11.

In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.

Upton AM, Cho S, Yang TJ, Kim Y, Wang Y, Lu Y, Wang B, Xu J, Mdluli K, Ma Z, Franzblau SG.

Antimicrob Agents Chemother. 2015 Jan;59(1):136-44. doi: 10.1128/AAC.03823-14. Epub 2014 Oct 20.

12.

1,4-azaindole, a potential drug candidate for treatment of tuberculosis.

Chatterji M, Shandil R, Manjunatha MR, Solapure S, Ramachandran V, Kumar N, Saralaya R, Panduga V, Reddy J, Prabhakar KR, Sharma S, Sadler C, Cooper CB, Mdluli K, Iyer PS, Narayanan S, Shirude PS.

Antimicrob Agents Chemother. 2014 Sep;58(9):5325-31. doi: 10.1128/AAC.03233-14. Epub 2014 Jun 23.

13.

Tuberculosis drug discovery and emerging targets.

Mdluli K, Kaneko T, Upton A.

Ann N Y Acad Sci. 2014 Sep;1323:56-75. doi: 10.1111/nyas.12459. Epub 2014 Jun 11. Review.

PMID:
24920100
14.

Lead optimization of 1,4-azaindoles as antimycobacterial agents.

Shirude PS, Shandil RK, Manjunatha MR, Sadler C, Panda M, Panduga V, Reddy J, Saralaya R, Nanduri R, Ambady A, Ravishankar S, Sambandamurthy VK, Humnabadkar V, Jena LK, Suresh RS, Srivastava A, Prabhakar KR, Whiteaker J, McLaughlin RE, Sharma S, Cooper CB, Mdluli K, Butler S, Iyer PS, Narayanan S, Chatterji M.

J Med Chem. 2014 Jul 10;57(13):5728-37. doi: 10.1021/jm500571f. Epub 2014 Jun 20.

PMID:
24874895
15.

Identification of a small molecule with activity against drug-resistant and persistent tuberculosis.

Wang F, Sambandan D, Halder R, Wang J, Batt SM, Weinrick B, Ahmad I, Yang P, Zhang Y, Kim J, Hassani M, Huszar S, Trefzer C, Ma Z, Kaneko T, Mdluli KE, Franzblau S, Chatterjee AK, Johnsson K, Mikusova K, Besra GS, F├╝tterer K, Robbins SH, Barnes SW, Walker JR, Jacobs WR Jr, Schultz PG.

Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):E2510-7. doi: 10.1073/pnas.1309171110. Epub 2013 Jun 17. Erratum in: Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15848. Robbins, Scott H [added]; Barnes, S Whitney [added]; Walker, John R [added]; Johnson, Kai [corrected to Johnsson, Kai].

16.

Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.

Dutta NK, Alsultan A, Gniadek TJ, Belchis DA, Pinn ML, Mdluli KE, Nuermberger EL, Peloquin CA, Karakousis PC.

Antimicrob Agents Chemother. 2013 Aug;57(8):3910-6. doi: 10.1128/AAC.00761-13. Epub 2013 Jun 3.

17.

Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.

Wells WA, Boehme CC, Cobelens FG, Daniels C, Dowdy D, Gardiner E, Gheuens J, Kim P, Kimerling ME, Kreiswirth B, Lienhardt C, Mdluli K, Pai M, Perkins MD, Peter T, Zignol M, Zumla A, Schito M.

Lancet Infect Dis. 2013 May;13(5):449-58. doi: 10.1016/S1473-3099(13)70025-2. Epub 2013 Mar 24. Review.

18.

Reply to "Contradictory results with high-dosage rifamycin in mice and humans".

Nuermberger EL, Rosenthal IM, Tasneen R, Peloquin CA, Mdluli KE, Karakousis PC, Grosset JH.

Antimicrob Agents Chemother. 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12. No abstract available.

19.

Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.

Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli K, Angulo-Barturen I, Dick T, Dartois V, Lenaerts AJ.

Tuberculosis (Edinb). 2012 Nov;92(6):453-88. doi: 10.1016/j.tube.2012.07.003. Epub 2012 Aug 30. Review.

20.

In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters.

Xu J, Lu Y, Fu L, Zhu H, Wang B, Mdluli K, Upton AM, Jin H, Zheng M, Zhao W, Li P.

Int J Tuberc Lung Dis. 2012 Aug;16(8):1119-25. doi: 10.5588/ijtld.11.0752. Epub 2012 Jun 12.

PMID:
22691726
21.

Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.

Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2012 Aug;56(8):4331-40. doi: 10.1128/AAC.00912-12. Epub 2012 Jun 4.

22.

Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.

Dutta NK, Illei PB, Peloquin CA, Pinn ML, Mdluli KE, Nuermberger EL, Grosset JH, Karakousis PC.

Antimicrob Agents Chemother. 2012 Jul;56(7):3726-31. doi: 10.1128/AAC.00500-12. Epub 2012 Apr 30.

23.

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother. 2012 Jun;56(6):3114-20. doi: 10.1128/AAC.00384-12. Epub 2012 Apr 2.

24.

Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.

Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother. 2011 Dec;55(12):5485-92. doi: 10.1128/AAC.05293-11. Epub 2011 Sep 19.

25.

Challenges and opportunities in developing novel drugs for TB.

Kaneko T, Cooper C, Mdluli K.

Future Med Chem. 2011 Sep;3(11):1373-400. doi: 10.4155/fmc.11.115. Review.

PMID:
21879843
26.

Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.

Ahmad Z, Minkowski A, Peloquin CA, Williams KN, Mdluli KE, Grosset JH, Nuermberger EL.

Antimicrob Agents Chemother. 2011 Apr;55(4):1781-3. doi: 10.1128/AAC.01514-10. Epub 2011 Jan 31.

27.

Mycobacterium tuberculosis DNA gyrase as a target for drug discovery.

Mdluli K, Ma Z.

Infect Disord Drug Targets. 2007 Jun;7(2):159-68. Review.

PMID:
17970226
28.

A Novel indole compound that inhibits Pseudomonas aeruginosa growth by targeting MreB is a substrate for MexAB-OprM.

Robertson GT, Doyle TB, Du Q, Duncan L, Mdluli KE, Lynch AS.

J Bacteriol. 2007 Oct;189(19):6870-81. Epub 2007 Jul 20.

29.

Mechanisms of isoniazid resistance in Mycobacterium tuberculosis.

Barry CE 3rd, Slayden RA, Mdluli K.

Drug Resist Updat. 1998;1(2):128-34.

PMID:
16904399
30.

Novel targets for tuberculosis drug discovery.

Mdluli K, Spigelman M.

Curr Opin Pharmacol. 2006 Oct;6(5):459-67. Epub 2006 Aug 9. Review.

PMID:
16904376
31.

Molecular validation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa.

Mdluli KE, Witte PR, Kline T, Barb AW, Erwin AL, Mansfield BE, McClerren AL, Pirrung MC, Tumey LN, Warrener P, Raetz CR, Stover CK.

Antimicrob Agents Chemother. 2006 Jun;50(6):2178-84.

32.
33.

Potent, novel in vitro inhibitors of the Pseudomonas aeruginosa deacetylase LpxC.

Kline T, Andersen NH, Harwood EA, Bowman J, Malanda A, Endsley S, Erwin AL, Doyle M, Fong S, Harris AL, Mendelsohn B, Mdluli K, Raetz CR, Stover CK, Witte PR, Yabannavar A, Zhu S.

J Med Chem. 2002 Jul 4;45(14):3112-29.

PMID:
12086497
34.

Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis.

DeBarber AE, Mdluli K, Bosman M, Bekker LG, Barry CE 3rd.

Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9677-82.

35.

AhpC, oxidative stress and drug resistance in Mycobacterium tuberculosis.

Sherman DR, Mdluli K, Hickey MJ, Barry CE 3rd, Stover CK.

Biofactors. 1999;10(2-3):211-7. Review.

PMID:
10609885
36.

Mycolic acids: structure, biosynthesis and physiological functions.

Barry CE 3rd, Lee RE, Mdluli K, Sampson AE, Schroeder BG, Slayden RA, Yuan Y.

Prog Lipid Res. 1998 Jul-Aug;37(2-3):143-79. Review. No abstract available.

PMID:
9829124
37.

Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.

Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Pan X, Mead D, Crane DD, Musser JM, Barry CE 3rd.

Science. 1998 Jun 5;280(5369):1607-10.

38.

Mechanisms involved in the intrinsic isoniazid resistance of Mycobacterium avium.

Mdluli K, Swanson J, Fischer E, Lee RE, Barry CE 3rd.

Mol Microbiol. 1998 Mar;27(6):1223-33.

39.

Mycobacterium tuberculosis efpA encodes an efflux protein of the QacA transporter family.

Doran JL, Pang Y, Mdluli KE, Moran AJ, Victor TC, Stokes RW, Mahenthiralingam E, Kreiswirth BN, Butt JL, Baron GS, Treit JD, Kerr VJ, Van Helden PD, Roberts MC, Nano FE.

Clin Diagn Lab Immunol. 1997 Jan;4(1):23-32.

40.

Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis.

Mdluli K, Sherman DR, Hickey MJ, Kreiswirth BN, Morris S, Stover CK, Barry CE 3rd.

J Infect Dis. 1996 Nov;174(5):1085-90.

PMID:
8896513
41.

Drug sensitivity and environmental adaptation of mycobacterial cell wall components.

Barry CE 3rd, Mdluli K.

Trends Microbiol. 1996 Jul;4(7):275-81. Review.

PMID:
8829336
42.

Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis.

Sherman DR, Mdluli K, Hickey MJ, Arain TM, Morris SL, Barry CE 3rd, Stover CK.

Science. 1996 Jun 14;272(5268):1641-3.

PMID:
8658136
43.

New vectors for the in vitro generation of alkaline phosphatase fusions to proteins encoded by G+C-rich DNA.

Mdluli KE, Treit JD, Kerr VJ, Nano FE.

Gene. 1995 Mar 21;155(1):133-4.

PMID:
7698658
44.

Serum-sensitive mutation of Francisella novicida: association with an ABC transporter gene.

Mdluli KE, Anthony LS, Baron GS, McDonald MK, Myltseva SV, Nano FE.

Microbiology. 1994 Dec;140 ( Pt 12):3309-18.

PMID:
7881549
46.
47.

Supplemental Content

Loading ...
Support Center